In 2016, Kim’s group designed reagent 13 by combining the topoisomerase I drug 7-ethyl-10-hydroxycamptothecin (SN-38) with hydroquinone (activated by NQO1) and biotin for targeting cancer cells [155]. The gene discussed is NQO1; the disease is cancer.